Skip to content

AHA/ASA 2026: acute ischaemic stroke

International AHA/ASA Current

2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke

Prabhakaran S, et al. Stroke. 2026;57:e316–e436
DOI 10.1161/STR.0000000000000513 · Summary checked against the source: 2026-11

Read or download the original

At a glance

  1. Tenecteplase or alteplase within 4.5 h. Tenecteplase 0.25 mg/kg (max 25 mg) as a single bolus; alteplase 0.9 mg/kg (max 90 mg). Tenecteplase 0.4 mg/kg is not recommended. [1, A · e357]
  2. Treat a disabling deficit fast, whatever the NIHSS. Within 4.5 h, don't wait for CTA or perfusion imaging before IVT. [1, B-NR · e353]
  3. Mild non-disabling stroke (e.g. isolated sensory deficit): IVT gives no benefit. Use DAPT instead. [3: No benefit, B-R · e353]
  4. Extended-window IVT with imaging: wake-up stroke with DWI–FLAIR mismatch, or 4.5–9 h with salvageable penumbra on perfusion imaging. [2a, B-R · e359]
  5. EVT now covers large cores. ASPECTS 3–5 is Class 1 at 0–6 h, and at 6–24 h if age <80 without significant mass effect. ASPECTS 0–2 is 2a at 0–6 h. [e368–e369]
  6. Basilar artery occlusion, NIHSS ≥10: EVT within 24 h is Class 1. [1, A · e372]
  7. Don't push BP too low. After IVT, a target SBP <140 gives no benefit. After successful EVT, SBP <140 for 72 h is harmful. [e350]
  8. Glucose: aim for 140–180 mg/dL. Intensive control to 80–130 mg/dL gives no benefit and causes hypoglycaemia. [e352]
  9. Children get recommendations for the first time, including EVT from age 28 days. [e375–e376]

Emergency evaluation and imaging

Class 1 [e341–e346]

  • NIHSS to measure the deficit at baseline and after reperfusion. [1, B-NR · e341]
  • Emergent NCCT or MRI before any reperfusion treatment, to exclude haemorrhage and judge ischaemic burden (ASPECTS). Aim for imaging within 25 minutes. [1, A · e341]
  • Suspected LVO: CTA/MRA from the neck to the head as fast as possible for EVT selection, up to 24 h from last known well. [1, A · e342]
  • Don't wait for serum creatinine before contrast CTA or CTP. [1, B-NR · e341]
  • Check blood glucose before IVT, since hypo- and hyperglycaemia mimic stroke. [1, B-NR · e353]
  • ECG and troponin, but neither should delay IVT or EVT. [e346]

Class 2a [e341–e342]

  • Wake-up or unknown-onset stroke >4.5 h: use MRI DWI–FLAIR mismatch to select for IVT. [2a, B-R · e341]
  • 4.5–24 h: use CTP or MR DWI–PWI with automated software to select for IVT. [2a, B-R · e342]
  • 6–24 h with LVO: adjunctive CTP or MRI can help select for EVT, if immediately available. [2a, A · e342]
  • Children: MRI/MRA first. Use CT/CTA if MRI isn't available within 25 minutes. [2a, C-LD · e341]

General supportive care

Area Recommendation Grade
Oxygen Give if SpO₂ ≤94%, to keep it >94% 1, C-LD
Routine oxygen without hypoxia (not for EVT): no benefit 3: No benefit, B-R
Head position Flat (0°) versus 30° for 24 h: no benefit 3: No benefit, B-R
Temperature Treat hyperthermia to normothermia and look for its cause 1, B-R
Induced hypothermia or prophylactic fever prevention: no benefit 3: No benefit, B-R
Glucose Treat hypoglycaemia <60 mg/dL 1, C-LD
Keep persistent hyperglycaemia at 140–180 mg/dL 2a, C-LD
IV insulin to reach 80–130 mg/dL: no benefit 3: No benefit, A

Adapted from AHA/ASA 2026 sections 4.1–4.5 [e347–e353]

Blood pressure

Situation Target Grade
Before IVT Lower to <185/110 mm Hg 1, B-NR
Before EVT, no IVT ≤185/110 mm Hg is reasonable 2a, B-NR
After IVT, first 24 h Keep <180/105 mm Hg 1, B-R
After IVT Intensive SBP <140: no benefit 3: No benefit, B-R
During and 24 h after EVT ≤180/105 mm Hg is reasonable 2a, B-NR
After successful EVT (mTICI 2b–3) SBP <140 for 72 h is harmful 3: Harm, A
No reperfusion, BP <220/120 Starting antihypertensives in the first 48–72 h: no benefit 3: No benefit, A
No reperfusion, BP ≥220/120 Benefit of treating in the first 48–72 h uncertain 2b, C-EO
Comorbidity needing BP control (ACS, acute HF, dissection, post-IVT sICH, pre-eclampsia) Treat early 1, C-EO

Adapted from AHA/ASA 2026 section 4.3 [e350]

Intravenous thrombolysis

Class 1: deciding on IVT [e353]

  • Disabling deficit, whatever the NIHSS: treat, and faster treatment means better outcome. [1, A · e353]
  • Within 4.5 h, start as quickly as possible, without waiting for multimodal imaging. [1, B-NR · e353]
  • Early ischaemic change of mild to moderate extent (short of frank hypodensity) doesn't exclude IVT. [1, A · e353]
  • Patients on single or dual antiplatelets can still have IVT. [1, B-NR · e353]
  • Don't wait for an MRI to exclude microbleeds. [1, B-NR · e353]
  • If disabling symptoms persist after correcting severe hypo- or hyperglycaemia, give IVT. [1, C-LD · e353]
  • Be ready to treat bleeding and orolingual angioedema. [1, B-NR · e353]

Class 2a and 2b

  • Don't delay IVT for coagulation results unless an abnormal result is suspected. [2a, B-NR · e353]
  • 1–10 microbleeds on a previous MRI: IVT is reasonable. More than 10: usefulness uncertain. [2a/2b, B-NR · e353–e354]
  • Sickle cell disease: IVT can be beneficial. [2a, B-NR · e362]
  • LVO with penumbra at 4.5–24 h and EVT not possible: IVT may be beneficial. [2b, B-R · e359]
  • Reteplase or mutant prourokinase instead of alteplase may be considered. [2b, B-R · e360]
  • Children aged 28 days to 18 years, within 4.5 h with a disabling deficit: alteplase may be considered. [2b, C-LD · e354]

Class 3

  • Mild non-disabling deficit within 4.5 h: no benefit from IVT. [3: No benefit, B-R · e353]
  • Tenecteplase 0.4 mg/kg: no benefit. [3: No benefit, A · e357]
  • Streptokinase: harmful, with higher early mortality. [3: Harm, A · e361]
  • Sonothrombolysis, and adjunctive argatroban or eptifibatide with IVT: no benefit. [e361, e378, e384]
  • IV aspirin within 90 minutes of starting IVT: harmful. [3: Harm, B-R · e378]

Doses and monitoring

Agent Dose
Alteplase 0.9 mg/kg (max 90 mg) over 60 min, 10% as a bolus over 1 min
Tenecteplase 0.25 mg/kg (max 25 mg) single IV push
Weight Tenecteplase Volume
<60 kg 15 mg 3 mL
60 to <70 kg 17.5 mg 3.5 mL
70 to <80 kg 20 mg 4 mL
80 to <90 kg 22.5 mg 4.5 mL
≥90 kg 25 mg 5 mL
  • Admit to an ICU or stroke unit.
  • BP and neuro checks every 15 min for 2 h, every 30 min for 6 h, then hourly to 24 h.
  • New headache, acute hypertension, vomiting or neurological worsening: stop the infusion and get an emergency CT.
  • Delay NG tubes, urinary catheters and arterial lines if you safely can.
  • CT or MRI at 24 h before starting antiplatelets or anticoagulants.

Adapted from AHA/ASA 2026 Table 7 [e358]

Extended window

Class 2a, LOE B-R [e359]

  • Unknown onset, within 4.5 h of symptom recognition: IVT if the DWI lesion is under one-third of the MCA territory with no marked FLAIR change.
  • Not eligible for EVT, with salvageable penumbra on automated perfusion imaging: IVT if they woke up within 9 h of the midpoint of sleep, or are 4.5–9 h from last known well.

Contraindications and cautions

The 2026 guideline replaces the old fixed contraindication list with a graded table (Table 8): conditions where benefit usually outweighs bleeding risk, relative contraindications and absolute contraindications.

  • CT with haemorrhage, or extensive clear hypodensity that explains the symptoms
  • Moderate to severe traumatic brain injury within 14 days
  • Intracranial or spinal surgery within 14 days
  • Spinal cord injury within 3 months
  • Intra-axial intracranial neoplasm
  • Infective endocarditis
  • Aortic arch dissection
  • Severe coagulopathy: platelets <100 000/mm³, INR >1.7, aPTT >40 s or PT >15 s
  • ARIA (amyloid-related imaging abnormalities) or amyloid immunotherapy
  • Pre-existing disability or frailty
  • DOAC within 48 h: safety unknown; may be considered after an individual risk assessment
  • Ischaemic stroke within 3 months
  • Previous ICH (higher risk with amyloid angiopathy)
  • Major non-CNS trauma within 14 days, major surgery within 10 days, GI/GU bleeding within 21 days
  • Intracranial arterial dissection, unruptured vascular malformation
  • STEMI within 3 months, acute pericarditis, LA/LV thrombus
  • Active systemic malignancy
  • Pregnancy and post-partum: may be considered for moderate to severe stroke
  • Dural puncture or non-compressible arterial puncture within 7 days
  • TBI or neurosurgery 14 days to 3 months ago
  • Extracranial cervical dissection
  • Extra-axial neoplasm (e.g. meningioma), unruptured aneurysm
  • Stroke during or just after angiography
  • Remote GI/GU bleeding or MI
  • Recreational drug use
  • Uncertain diagnosis or possible mimic, if there's no absolute contraindication
  • Moyamoya disease

Adapted from AHA/ASA 2026 Table 8 [e364–e367]

Endovascular thrombectomy

Class 1, LOE A [e368]

  • Eligible for both IVT and EVT: give IVT, as fast as possible, and don't wait to see a response before EVT.
  • Techniques: stent retriever, contact aspiration or both. Aim for eTICI 2b/2c/3 as early as possible. General anaesthesia or procedural sedation are both acceptable. [e373]

Who gets EVT

This mirrors AHA/ASA 2026 Figure 3. Adults have NIHSS ≥6 unless stated otherwise. "IDD" means insufficient data to determine.

Time ASPECTS Pre-stroke mRS EVT
0–6 h 6–10 0–1 1
2 2a
3–4 2b
>4 IDD
0–6 h 3–5 0–1 1
≥2 IDD
0–6 h 0–2 0–1 2a (age <80, no significant mass effect)
≥2 IDD
6–24 h 6–10 0–1 1
6–24 h 3–5 0–1 1 (age <80, no significant mass effect)
6–24 h any ≥2 IDD
>24 h IDD
Occlusion Time Criteria EVT
Dominant proximal M2 0–6 h ASPECTS 6–10, mRS 0–1 2a
>6 h IDD
Non-dominant M2, or distal vessel (M3, ACA, PCA) 0–24 h No EVT (3: No benefit)
Basilar artery 0–24 h PC-ASPECTS ≥6, mRS 0–1, NIHSS ≥10 1
0–24 h PC-ASPECTS ≥6, mRS 0–1, NIHSS 6–9 2b
0–24 h mRS ≥2 IDD
Age Time Criteria EVT
≤28 days 0–24 h LVO IDD
28 days to 5 years 0–24 h LVO, salvageable brain 2b
6–17 years 0–6 h LVO, salvageable brain 2a
6–17 years 6–24 h LVO, salvageable brain 2a
6–17 years >24 h IDD

Adapted from AHA/ASA 2026 Figure 3 [e377]

Other EVT points

  • Tandem extracranial–intracranial occlusion: treating both, including emergency stenting, may be reasonable. [2b, B-NR · e373]
  • Intra-arterial thrombolytic after successful EVT (mTICI ≥2b) may be reasonable. [2b, B-R · e373]
  • Tirofiban before EVT: no benefit. [3: No benefit, B-R · e373]

Antiplatelets and anticoagulants

Class 1

  • Aspirin within 48 h of stroke onset. [1, A · e376]
  • Non-cardioembolic stroke or TIA: antiplatelets rather than anticoagulation. [1, A · e378]
  • Minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), no IVT: aspirin + clopidogrel with a loading dose, started within 24 h, for 21 days, then single antiplatelet. [1, A · e378]

Class 3

  • Aspirin instead of IVT or EVT in an eligible patient: harmful. [3: Harm, B-R · e378]
  • Triple antiplatelet therapy (aspirin + clopidogrel + dipyridamole): harmful. [3: Harm, B-R · e378]
  • Adding an antiplatelet to an oral anticoagulant in AF without recent stent or active CAD: harmful. [3: Harm, B-NR · e378]
  • IV abciximab: harmful. Ticagrelor alone rather than aspirin: no benefit. [e378]
  • Early anticoagulation within 48 h doesn't prevent early neurological worsening. [3: No benefit, A · e384]

DAPT for minor stroke and TIA

flowchart TD
    A["Acute non-cardioembolic<br/>ischaemic stroke or TIA"] --> B{"Eligible for<br/>revascularisation?"}
    B -->|Yes| T["Thrombolysis and<br/>thrombectomy sections"]
    B -->|No| C{"Last known well<br/>&lt;24 h?"}
    C -->|Yes| D{"NIHSS ≤3 or<br/>ABCD2 ≥4?"}
    C -->|No| E{"Atherosclerosis<br/>(&gt;50% stenosis)?"}
    E -->|No| S1["SAPT"]
    E -->|Yes| F{"24–72 h, and<br/>NIHSS ≤5 or ABCD2 ≥4?"}
    F -->|Yes| P1["DAPT: clopidogrel + aspirin × 21 days<br/>Class 2a (INSPIRES)"]
    F -->|No| S2["SAPT"]
    D -->|No| G{"NIHSS 4–5?"}
    G -->|No| S3["SAPT"]
    G -->|Yes| P2["DAPT: clopidogrel + aspirin × 21 days<br/>Class 2a (INSPIRES, presumed atherosclerosis)<br/>OR ticagrelor + aspirin × 30 days<br/>Class 2b (THALES)"]
    D -->|Yes| H["DAPT: clopidogrel + aspirin × 21–90 days<br/>Class 1 (CHANCE, POINT)<br/>OR ticagrelor + aspirin × 30 days<br/>Class 2b (THALES)"]
    D -.->|"If allele testing done"| K{"CYP2C19 loss-of-<br/>function carrier?"}
    K -->|No| H
    K -->|Yes| P3["DAPT: ticagrelor + aspirin × 21 days<br/>Class 2b (CHANCE-2)"]
Adapted from AHA/ASA 2026 Figure 4 [e379]

Anticoagulation

  • AF: in carefully selected (e.g. milder) strokes, early oral anticoagulation is reasonable and low risk compared with delayed. [2a, A · e384]
  • Cervical artery dissection: antiplatelet or anticoagulant for at least 3 months. [2a, B-R · e378]

In-hospital care

Area Recommendation Grade
Stroke unit Organised stroke unit with an interdisciplinary team 1, B-R
Swallowing Bedside swallow screen before any food or drink 1, C-EO
Nutrition Start enteral feeding within 7 days. NG tube first; PEG if unable to swallow safely for >2–3 weeks 1, B-R / 2a, B-NR
DVT Intermittent pneumatic compression in immobile patients 1, B-R
Prophylactic UFH or LMWH is reasonable 2a, B-R
Elastic compression stockings: harmful 3: Harm, B-R
Depression Screen with a structured inventory; treat with antidepressants and/or therapy 1, B-NR / 1, B-R
Catheters No routine indwelling bladder catheter 3: Harm, C-LD
Antibiotics No routine prophylactic antibiotics 3: No benefit, A
Rehabilitation Formal interdisciplinary rehabilitation 1, A
Very early, high-dose mobilisation within 24 h: may be harmful 3: Harm, B-R
SSRIs to aid motor recovery: no benefit 3: No benefit, A

Adapted from AHA/ASA 2026 sections 5.1–5.7 [e389–e396]

Brain swelling and seizures

Class 1

  • Large hemispheric or cerebellar infarct: discuss goals of care early, monitor closely in the first days, and transfer early to a centre with neurosurgery. [e397]
  • Age ≤60, unilateral MCA infarct, worsening within 48 h despite medical treatment: decompressive craniectomy with dural expansion. [1, A · e398]
  • Cerebellar infarct with obstructive hydrocephalus: ventriculostomy. [1, C-LD · e400]
  • Cerebellar infarct with brainstem compression or volume ≥35 mL: suboccipital decompressive craniectomy. [1, B-NR · e400]
  • Unprovoked seizure after stroke: start an antiseizure drug. [1, C-LD · e400]

Class 2a and 2b

  • Osmotic therapy as a bridge to surgery. [2a, C-LD · e398]
  • Falling consciousness from swelling is a reasonable trigger for hemicraniectomy. [2a, B-NR · e398]
  • Age >60: craniectomy may be considered to reduce mortality. [2b, B-R · e398]

Class 3

  • Hypothermia, barbiturates or corticosteroids for brain swelling: harmful. [3: Harm, C-LD · e398]
  • IV glibenclamide in large hemispheric infarction: no benefit. [3: No benefit, B-R · e398]
  • Prophylactic antiseizure drugs: no benefit. [3: No benefit, C-LD · e400]

Clinical pearls

  • Time windows: IVT ≤4.5 h (up to 9 h, or wake-up, with imaging). EVT ≤24 h for anterior LVO and basilar occlusion.
  • Tenecteplase 0.25 mg/kg, max 25 mg, bolus. Alteplase 0.9 mg/kg, max 90 mg, 10% bolus then the rest over 60 min.
  • BP <185/110 before IVT, <180/105 for 24 h after.
  • Glucose before IVT. Keep 140–180 mg/dL; avoid hypoglycaemia (<60).
  • Minor stroke or high-risk TIA: aspirin + clopidogrel within 24 h for 21 days.
  • Malignant MCA infarct, age ≤60: craniectomy within 48 h of deterioration.
  • No steroids for oedema, prophylactic antiseizure drugs, compression stockings or routine catheters.

Classes and levels of evidence

How AHA/ASA 2026 grades its recommendations. Adapted from AHA/ASA 2026 Table 2 [e324]. Hover over any class or level cited on this page to see what it means.

Class Strength Meaning Wording used
Class 1 Strong Benefit >>> risk is recommended; is indicated, useful, effective or beneficial; should be performed or administered
Class 2a Moderate Benefit >> risk is reasonable; can be useful, effective or beneficial
Class 2b Weak Benefit ≥ risk may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain
Class 3: No benefit Moderate Benefit = risk (generally used only with level A or B) is not recommended; is not indicated, useful or effective; should not be performed or administered
Class 3: Harm Strong Risk > benefit potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered
Level Meaning
Level A High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies
Level B-R (randomised) Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs
Level B-NR (non-randomised) Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies
Level C-LD (limited data) Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans
Level C-EO (expert opinion) Consensus of expert opinion based on clinical experience

Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.